[關(guān)鍵詞]
[摘要]
銀屑病是一種常見的皮膚疾病,其特征是慢性炎癥性病變,長期困擾患者且不易為醫(yī)生治療。雖然有多種治療方案可供選擇,但都有其局限性,因此急需一種有效、安全的口服治療銀屑病的藥物。阿普司特作為磷酸二酯酶-4(PDE-4)抑制劑,是一種口服藥物,抑制參與銀屑病發(fā)病機(jī)制中的多個(gè)炎癥標(biāo)志物的活性,可有效治療銀屑病。阿普司特在一系列臨床研究中顯示出良好的治療前景,且安全性及耐受性均較好。
[Key word]
[Abstract]
Psoriasis is a common skin disorder characterized by chronic inflammatory lesions. Patients are frequently troubled by it and it is difficult for doctor to cure. Although multiple therapeutic options are available, they all have limitations. There is an urgent need for an effective, safe, and oral drug used in clinic for the treatment of psoriasis. Apremilast, as an inhibitor of phosphodiesterase-4 (PDE-4), is an oral medication that inhibits the activity of multiple inflammatory markers involved in the pathogenesis of psoriasis. It can be used to treat psoriasis effectively, which shows a good prospect in a series of clinical studies with good safety and tolerability.
[中圖分類號(hào)]
[基金項(xiàng)目]
天津市科技計(jì)劃項(xiàng)目(13ZCZDSY00100)